54 results about "Deoxyuridine" patented technology

Provided is a method for preparing purine nucleoside. The preparation method comprises catalyzing a uridine substrate and a substrate base by using a pyrimidine nucleoside phosphorylase and a purine nucleoside phosphorylase, and preparing and obtaining purine nucleoside. The uridine substrate comprises uridine, 2'-deoxyuridine or 2'-amino-2'-deoxyuridine, and the substrate base comprises a purine compound, wherein on the purine compound, R1 comprises -NH 2,-OCH 3 or -Cl, and R2 comprises -NH 2, -F or -Cl. The preparation method can solve the problem of low yield in the preparation of nucleoside compounds in the prior art, and is suitable for the field of enzymatic catalysis.

The invention discloses a synthesis method of 2 '-fluoro-2'-deoxyguanosine. According to the method, thymine nucleoside phosphorylase and purine nucleoside phosphorylase are used as biocatalysts, and 2 '-fluoro-2'-deoxyuridine and guanine are used as substrates to synthesize the 2 '-fluoro-2'-deoxyguanosine. Compared with a chemical method, the production cost is greatly reduced; meanwhile, the synthesis method can effectively solve the problem that the product is difficult to separate.

The invention provides a method of inducing a DNA-encoded library (DEL) comprising cleavable site(s) in the DNA strand to a cross linker-modified double-stranded DEL and evaluating the DEL. Both the merits of the hairpin-stranded DEL and the double-stranded DEL are achieved in the invention by introducing the cleavable site(s) such as deoxyuridine into the DNA strand. The invention further provides a technique for screening a compound in which both “simple DEL synthesis method” and “expansion and improvement of the DEL evaluation method” are achieved by easily inducing the compound into a cross linker-modified DEL.

The invention belongs to the technical field of bioengineering, and particularly provides a preparation method of a nucleoside analogue, which comprises the following steps: by taking 2 '-fluoro-2'-deoxyuridine and a compound as shown in a formula I as substrates, reacting under the catalysis of an enzyme to generate a compound as shown in a formula II.

The invention relates to a novel method for preparing 5-fluoro-2 '-deoxyuridine-5'-O-[1-naphthyl (benzyloxy-L-alanine)] phosphate (NUC-3373) and a derivative of the NUC-3373. The NUC-3373 produced according to the method is more stable than NUC-3373 produced according to other methods. # imgabs0 #

The invention discloses a reagent and a method for improving the tolerance of a PCR inhibitor and application, and belongs to the technical field of molecular biology. According to the invention, the thermosensitive uracil DNA glycosidase and the deoxyuridine triphosphate are combined and used as the PCR antiinhibitor to be applied to DNA amplification of a whole blood sample, and experiments prove that the composition can improve the endurance capacity of a PCR reaction system to a whole blood inhibitor, reduce the false negative rate and improve the accuracy and reliability of detection. Meanwhile, the method for carrying out PCR reaction by using the composition is simple to operate, low in cost and high in nucleic acid detection sensitivity. Therefore, the reagent and the method have a good application prospect in detection of nucleic acid extracted from a whole blood sample.

The invention discloses pyridine DPP fluorophore extension type deoxyuridine as well as a preparation method and application thereof, and belongs to the field of biological medicine and detection. The invention provides a uridine analogue modified by a fluorescent chromophore DPP derivative with a structure shown in the specification, and pyridine DPP fluorophore extension type deoxyuridine has excellent fluorescent property, can be used as a fluorescent probe, and is widely applied to the fields of biochemistry, medicine and the like.

The invention relates to methods and pharmaceutical compositions for use of a deoxyuridine 5'-triphosphate nucleotidohydrolase (DUT) inhibitor for the treatment of resistant HRD cancer, particularly resistant BRCA-associated cancer.

To provide a method for producing 5-fluoro-2' - deoxyuridine-5' -O - [1-naphthyl (benzyloxy-L-alaninyl)] phosphate (NUC-3373) and a method for producing 3' - deoxyadenosine-5' -O - [phenyl (benzyloxy-L-alaninyl)] phosphate (NUC-7738).SOLUTION: A compound of Formula (IIa) or (IIb) is reacted with a compound of Formula (IIIa) or (IIIb), respectively, in presence of a base (B1) and the protecting groups are removed from the resulting compound of Formula (IVa) or (IVb) to provide NUC-3373 or NUC-7738.SELECTED DRAWING: None

The invention discloses a method for rapidly detecting MTHFR (Methylene Tetrahydrofolate Reductase) gene polymorphism based on a complementary probe technology, which comprises the following steps: S1, acquiring a sample: extracting genome DNA (Deoxyribose Nucleic Acid) from a sample to be detected as an amplification template; s2, preparing a reaction system: adding the genome DNA, the upstream primer, the downstream primer, the C probe, the T probe, uracil-N-glycosylase, DNA polymerase, deoxyribonucleoside triphosphate and deoxyuridine triphosphate of the sample to be detected into the reaction system; s3, carrying out PCR (Polymerase Chain Reaction) amplification reaction under the conditions that the temperature is 90-98 DEG C, and the time is 5-20 minutes; performing denaturation at the temperature of 90-98 DEG C for 10-50 seconds; the temperature is 55-69 DEG C, and annealing is conducted for 60-120 s; the temperature is 68-72 DEG C, and extension is carried out for 15-300 s; carrying out 35 to 40 cycles; and S, genotype judgment. A test result is the same as a first-generation sequencing test result, which shows that the detection method of the scheme has relatively high accuracy. Meanwhile, compared with a sequencing method, the method has the advantages that a series of complex follow-up treatment does not need to be carried out on a PCR product, PCR amplification and detection are synchronously carried out, the detection time is greatly shortened, and the detection cost is reduced.

The present invention belongs to the field of organic synthesis and specifically relates to a method for synthesizing 2'-fluoro-2'-deoxyuridine and its intermediates. The method comprises the following steps: The method prepares 2'-fluoro-2'-deoxyuridine by constructing novel intermediates, namely, compounds of formula IV, III, and II. This method avoids the use of reagents such as dihydropyran, which are strong eye and skin irritants. The method results in milder reaction conditions, lower costs, simple operation, environmental friendliness, high yield, and suitability for industrial production.

The invention relates to the technical field of medicines, in particular to a borate compound as well as a preparation method and application thereof. Wherein the structural formula of the boric acid ester compound is as shown in I. According to the invention, through molecular structure design, 3-carboxyl is utilized for modification, water solubility and intramolecular hydrogen bonds are enhanced, hydrolysis is inhibited, and stability is improved; a uracil structure is utilized, thymidine / deoxyuridine is simulated, the thymidine / deoxyuridine is actively taken by TK1 high-expression cancer cells and is enriched near DNA in a targeted manner, the BNCT efficiency is improved, and a novel boron drug with high water solubility, stability and targeting property is successfully developed. # imgabs0 #

The present invention belongs to the technical field of preparing functional materials for molecular recognition, adsorption and separation, and discloses a method for preparing a hydrophilic dual-receptor MOFs nanosheet surface imprinted adsorbent and its application in the selective separation of adenosine monophosphate. The present invention targets the structural characteristics of a typical nucleoside compound adenosine monophosphate (AMP) molecule, designs and synthesizes Zr-MOFs nanosheets coordinated with its specific metal ion as a matrix material, and uses 5-(2-methoxyvinyl)-2′-deoxyuridine (AcrU) as a functional monomer that undergoes specific base complementary pairing. The arrangement and orientation of the template molecules are precisely fixed through an ordered assembly strategy. Finally, the large number of double bonds modified on the surface of the Zr-MOFs nanosheets and a hydrophilic cross-linking agent are utilized to photoinitiate the construction of a stable hydrophilic dual-receptor MOFs nanosheet surface imprinted adsorbent (D-MIPs), thereby enhancing the recognition and separation effect of nucleoside compounds and achieving the selective separation and enrichment of nucleoside compounds such as AMP in biological samples such as urine and blood.

Polymer compounds useful for preparing antibody-drug conjugates are disclosed. The polymers contain a side chain-carrying deoxyuridine group. Methods associated with preparation and use of such compounds are also provided.

The embodiment of the invention provides a connecting unit for chemical modification of a nucleic acid terminal group, a solid-phase carrier and a preparation method of the solid-phase carrier, the chemical modification comprises N-acetylgalactosamine, and the method comprises the following steps: mixing L-deoxyuridine with iodine, and carrying out iodine substitution reaction to obtain 8-iodine-L-deoxyuridine; carrying out triphenyl methylation on the 8-iodine-L-deoxyuridine to protect 5 '-terminal hydroxyl, carrying out palladium catalytic coupling reaction to obtain 8-alkenyl-L-deoxyuridine ester compounds, and hydrolyzing to obtain unsaturated carboxyl modified L-deoxyuridine derivatives; the unsaturated carboxyl modified L-deoxyuridine derivative and N-acetylgalactosamine are subjected to condensation, and the connecting unit for nucleic acid end group chemical modification is obtained. The connection unit obtained by the method has better enzymolysis resistance, and the synthesis method is simple and efficient.

The invention discloses a drug delivery nano system based on ROS response as well as a preparation method and application of the drug delivery nano system. The drug delivery nano system comprises nanoparticles and a camptothecin-5-fluorodeoxyuridine prodrug, wherein the nanoparticles are formed by self-assembly of an amphiphilic high-molecular polymer HA-IR-780 with a photosensitive characteristic, and the camptothecin-5-fluorodeoxyuridine prodrug is wrapped in the nanoparticles; and the surface of the drug delivery nano system is modified with a lipid-polyethylene glycol material. When the drug delivery nano-system is applied to preparation of breast cancer drugs, the drug delivery nano-system can be enriched at a tumor site depending on the passive targeting effect of the EPR effect of the drug delivery nano-system, breast cancer chemotherapy / PDT / PTT / combined treatment can be achieved, and the effects of reducing toxicity and enhancing efficacy are achieved to a certain extent.

The invention discloses DPP derivative modified deoxyuridine as well as a synthesis method and application thereof, and belongs to the field of biological medicine and detection. The invention provides DPP derivative modified deoxyuridine shown in the following structure, and the compound has excellent fluorescent property, can be used as a fluorescent probe, and is widely applied in the fields of biochemistry, medicine and the like, such as tools for specific drug delivery, molecular recognition and biosensing, and the like. Action # imgabs0 # in nucleic acid analysis and quantitative detection of fluorescence-labeled oligonucleotides and potential of the fluorescence-labeled oligonucleotides in treatment of human acquired diseases or genetic diseases, capability of specifically regulating gene expression and value of the fluorescence-labeled oligonucleotides in clinical application after chemical modification, as well as application of the fluorescence-labeled oligonucleotides in nucleic acid analysis and quantitative detection of the fluorescence-labeled oligonucleotides

The application discloses a monomerized pyrimidine nucleoside phosphorylase mutant and a construction method and application thereof, and belongs to the field of enzyme engineering and biological catalysis technology.The mutant is obtained by amino acid substitution mutation of wild-type pyrimidine nucleoside phosphorylase shown in SEQ ID NO:1, and the amino acid sequence is shown in SEQ ID NO:2.The mutant is transformed into a stable monomer form by dimer interface remodeling and hinge region stabilization of the closed active conformation, the natural dimer PyNP is transformed into a stable monomer form, and the catalytic activity of the mutant to uridine, 2'-deoxyuridine and similar substrates is maintained in the monomer state.Compared with the wild-type enzyme, the mutant has lower oligomer dependence, better temperature stability, pH stability and storage stability, and can be used for biological catalytic synthesis of nucleosides and nucleoside analogs.

The present invention discloses a method for in vivo labeling of fish. After injecting a solution of 5-bromo-2'-deoxyuridine into the abdominal cavity of the fish according to the required injection dose, a fluorescent probe FITC-Keratin is then injected into the abdominal cavity of the fish. Subsequently, the intestinal support of the live fish is made into frozen sections, which are then subjected to antigen repair, circle sealing, addition of primary antibody, addition of secondary antibody, spontaneous fluorescence quenching, DAPI nuclear counterstaining, and then microscopic examination and photographing to collect images. The present invention is safe, efficient and accurate, and creatively combines the BrdU in vivo labeling method with the fluorescent probe technology and applies it to the research on the proliferation and migration of fish intestinal epithelial cells, providing a technical approach for studying the promoting effect of exogenous substances on the proliferation and migration of fish intestinal epithelial cells, and having very important significance for the efficient and healthy aquaculture of fish.

This invention relates to a novel process for the preparation of 5-fluoro-2′-deoxyuridine-5′—O-[1-naphthyl (benzoxy-L-alaninyl)] phosphate (NUC-3373) and derivatives thereof. The NUC-3373 made according to this process is more stable than NUC-3373 made according to alternative processes.

The invention relates to a hydantoin-containing deoxyuridine triphosphatase inhibitor and a preparation method thereof. Provided herein are dUTPase inhibitors, compositions comprising these compounds, and methods of using these compounds or compositions.

Described herein are synthetic methods for producing sequence-specific RNA oligonucleotides that eliminate impurities produced in prior art methods. In one aspect, a first amplification primer includes one or more deoxyuridine residues, wherein at least one of the one or more deoxyuridine residues is at position −1, −2, −3, −4 or −5 of the promoter region for the single-subunit, DNA-dependent RNA polymerase. The deoxyuridines are excised to provide an amplified functional template DNA which is then used to synthesize RNA which has reduced immunogenic double stranded RNA compared to controls.

The present disclosure provides pyrimidine nucleoside compounds, including torcitabine, thymidine, deoxyuridine, deoxycytidine and uridine, and methods to treat telomere biology disorders (TBDs) and aging-related diseases, including hematological disorder, liver disease, or hepatic fibrosis, comprising administering to a subject diagnosed with said telomere biology disorder a therapeutically effective amount of said compounds.

The invention discloses a fluorodeoxyuridine monophosphate prodrug as shown in a formula I, application of the prodrug in preparation of a medicine for treating liver cancer, a pharmaceutical composition containing the prodrug and pharmaceutically acceptable auxiliary materials or taraxasterol and application of the prodrug in preparation of the medicine for treating liver cancer, and belongs to the field of pharmacy. The compound is modified by specific natural amino acid residues and can be used for preparing medicines for treating liver cancer. The in-vitro and in-vivo anti-tumor activity of the compound is remarkably superior to that of the prior art, the compound has a synergistic effect when being combined with taraxasterol, the highest tumor inhibition rate reaches 91.72%, the compound is high in selectivity, good in safety and high in liver targeting performance, and a more effective new scheme is provided for liver cancer treatment.

The present invention relates to a polymer-based drug delivery system as such and its use in a method of treatment of a range of diseases and disorders, including cancer. The drug delivery system of the present invention is suitable for intracranial delivery and release of cytotoxic agents, in particular radioisotope-functionalized agents such as deoxyuridine.

The invention discloses a heterologous transport protein YdhP and application thereof in production of beta-thymidine from escherichia coli, and belongs to the technical field of microbial engineering. According to the present invention, by introducing the heterologous transport protein ydhP derived from Ralstania mannitolyticus, the extracellular secretion of beta-thymidine can be effectively promoted, and the intracellular feedback regulation limitation can be reduced; during shake flask fermentation, the yield of beta-thymidine is increased to 1.6 g / L (increased by about 45%), and the by-product deoxyuridine is reduced by about 50%; the yield in a 5 L fermentation tank reaches 20 g / L, which is obviously improved compared with that of a control strain (12 g / L), and an efficient and stable engineering strain and a fermentation process are provided for industrial production of beta-thymidine.

Provided are methods and compositions for activating oligonucleotide aptamer-deactivated DNA polymerases, comprising modifying the aptamer by uracil-DNA glycosylase enzymatic activity to reduce or eliminate binding of the oligonucleotide aptamer to the DNA polymerase, thereby activating DNA synthesis activity of the DNA polymerase in a reaction mixture. Mixtures for use in methods of the invention are also provided. In some aspects, the oligonucleotide aptamers are circular and comprise one or more deoxyuridine nucleotides providing for aptamer-specific recognition and modification of the circular aptamer by the uracil-DNA glycosylase enzymatic activity. Exemplary oligonucleotide aptamers, mixtures and methods employing uracil-DNA glycosylase enzymatic activity are provided. The methods can be practiced using kits comprising a DNA polymerase-binding oligonucleotide aptamer and at least one uracil-DNA glycosylase enzymatic activity having oligonucleotide aptamer-specific recognition to provide for specific modification of the aptamer by the uracil-DNA glycosylase enzymatic activity.

The present invention relates generally to the fields of cancer cell biology, cancer therapeutics for cancers located within in the central nervous system, thymidine analogs and cellular nucleotide excision repair mechanisms. More specifically, the invention relates to the use of EdU in methods of treating cancers located within in the central nervous system, and methods of inhibiting and / or reducing growth of a cancer or cancer cell.

Provided are a high-affinity nanoantibody targeting African swine fever virus deoxyuridine triphosphatase, and a preparation method therefor and a use thereof. The nanoantibody targeting African swine fever virus deoxyuridine triphosphatase has three complementarity determining regions CDR1, CDR2 and CDR3, wherein the amino acid sequence of CDR1 is positions 26-38 of SEQ ID No. 2, the amino acid sequence of CDR2 is positions 55-64 of SEQ ID No. 2, and the amino acid sequence of CDR3 is positions 100-113 of SEQ ID No. 2. Upon verification by ELISA, the nanoantibody can specifically bind to African swine fever virus deoxyuridine triphosphatase (dUTPase), and has relatively high affinity.